相关实验视频

Updated: Jun 21, 2025

Author Spotlight: Assessing the Olfactory Effects of Airborne Pollutants — Buried Food and Social Odor Tests

Author Spotlight: Assessing the Olfactory Effects of Airborne Pollutants — Buried Food and Social Odor Tests

Published on: September 13, 2024

福斯科林作为COVID-19后慢性嗅觉功能障碍的有希望的治疗方法的有效性

Mohamed H Abdelazim¹, Faisal Alsenani², Mohammed Alnuhait³

¹Department of Otolaryngology, Faculty of Medicine, Al-Azhar University, Damietta, Egypt.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery

|July 13, 2024

概括

口服福斯科林显著改善了COVID-19幸存者的嗅觉功能障碍. 这种治疗增强了气味识别和区分,为慢性气味丧失的恢复提供了希望.

科学领域:

神经学神经学
耳鼻喉科耳鼻喉科耳鼻喉科
药理学药理学是指药理学的学科.

背景情况:

嗅觉功能障碍是COVID-19感染后的一个普遍和令人痛苦的症状.
周期性腺单酸盐 (cAMP) 和周期性关单酸盐 (cGMP) 的降低水平与慢性嗅觉功能障碍有关.
一项前性随机临床试验旨在研究一种新的治疗方法.

研究的目的:

为了评估口服福斯科林的疗效,一个腺环酶激活剂,在治疗COVID-19后持续的嗅觉功能障碍.
为了比较福斯科林治疗与安慰剂在改善嗅觉功能的效果.

主要方法:

该研究包括285名患有COVID-19后嗅觉功能障碍的参与者.
参与者被随机分配,接受口服福斯科林 (n=165) 或安慰剂 (n=120) 囊.
嗅觉功能使用"嗅探棒"测试进行评估,测量值,歧视和识别分数治疗前后.

主要成果:

福斯科林组在复合TDI (值,歧视和识别) 评分上显示出显著的改善.
在福斯科林组内,在歧视和识别得分上观察到特定的增强.
与安慰剂相比,福斯科林组的值得分没有显著变化.

结论:

口服福斯科林显示出作为治疗剂的潜力,可以改善COVID-19中康复的个体的慢性嗅觉功能障碍.
这些发现表明,调节细胞内cAMP水平可能是治疗嗅觉障碍的可行策略.

关键词:

亚丁烯基基环酶是什么?临床研究是临床研究.福斯科林 (Forskolin) 是一种类型的 Forskolin.嗅觉功能障碍嗅觉功能障碍鼻子的棒棒.

更多相关视频

Modeling and Simulations of Olfactory Drug Delivery with Passive and Active Controls of Nasally Inhaled Pharmaceutical Aerosols

Modeling and Simulations of Olfactory Drug Delivery with Passive and Active Controls of Nasally Inhaled Pharmaceutical Aerosols

Published on: May 20, 2016

A Free-breathing fMRI Method to Study Human Olfactory Function

A Free-breathing fMRI Method to Study Human Olfactory Function

Published on: July 30, 2017

相关概念视频

COPD: Management Using Bronchodilators and Corticosteroids

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

Acute Respiratory Failure-V

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...